

PHAGE FUTURES

OCTOBER 25 2023

Digital Summit
phagefuturesdigital.com

**RESERVE
YOUR FREE
PASS
TODAY**

The leading platform accelerating the translation of bacteriophages into clinically and commercially viable and tangible commercial solutions

CONNECT

Take advantage of Q&As to ask our speakers your burning questions. Use our online networking platform to maximize your productivity. This event attracts the entire ecosystem of phage from leading biotech and pharma, to investors and academics making this an incredible opportunity to connect.

LEARN

We're uniting leading phage companies and stakeholders from across the world, giving a more comprehensive insight into the latest clinical trial data than ever before. Whether your interests lie in science, research, healthcare, agriculture, or drug development there is a session for you.

ENJOY

More people than ever will have access to the event, bringing together more diverse perspectives and content and networking opportunities, and allowing for a broader outlook on the landscape of phage therapy.

Summit Partner:



www.phagefuturesdigital.com

+44 (0) 203 696 2920

events@kisacoresearch.com

**Kisaco
Research**

WELCOME

Join us online at Phage Futures Global Digital Summit 2023

We have created a virtual stage upon which to initiate all-important discussions and forge partnerships between key stakeholders worldwide. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies and beyond.

Discover how you can be at the forefront of the developing phage therapy market.

Network and learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations, and regulatory bodies.

Key topics to hear and participate in:

Clinical Trials

Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic and acute illness



Regulation

Insights and discussions between international governing bodies with region-specific follow up conversations with the experts



Latest Data

The latest clinical data from the leading pharma and biotech companies developing phage therapeutics




Investment

Expert advice on how to find and secure financial investments, navigating the current investment landscape and future-proofing your organisation



MEET OUR INDUSTRY LEADING SPEAKERS



Robert McKee
Principal Scientist
Locus Biosciences



Iddo Weiner
Vice President of Research
BiomX



Greg German
Co-Founder
Phage Canada



Danish Malik
Senior Lecturer
Loughborough University



Mina Pastagia
Chief Medical Officer
Armata Pharmaceuticals



Kristin Wannerbeger
Director and R&D Alliance Manager
Ferring Pharmaceuticals



Jiayi Zhang
Founder & Chief Executive Officer
Start Bioservices



Matjaz Peterka
Chief Executive Officer
COBIK



Joseph Campbell
Research Resources Project Officer
NIH



Diane Shader Smith
Author & Cystic Fibrosis
Advocate



Justyna Kowalska
Head of Product Management
Proteon Pharmaceuticals



Tobi Nagel
Founder & President
Phages for Global Health



Carrie-Lynn Furr
Co-Founder & Chief Executive Officer
BDDC

PLAN YOUR DAY

6:00am

11:00am

Welcome and Introduction

6:10am

11:10am

Panel Discussion: Phage therapy - where we are & where we are going

- Outline the current clinical landscape and global potential of bacteriophage therapy
- Understanding the failed antibiotic market in order to establish commercial viability
- How do we get bacteriophage’s closer to clinical development?

Moderator: **Carrie Furr**, Co-Founder & Chief Executive Officer, **BDDC**
Kristin Wannerberger, Director and R&D Alliance Manager, **Ferring Pharmaceuticals**

6:30am

11:30 am

Scalable phage manufacturing using process analytical technologies to improve production

- Use of on-line sensors for Upstream (USP) production of phages in stirred-tank bioreactors
- Modelling and optimisation of USP phage production
- Downstream Processing of phages using Tangential Flow Filtration and Chromatography - Using MALDI-ToF, MADLS and other analytical approaches for phage drug substance characterisation and linking critical process parameters (CPP) with critical quality attributes (CQA)

Danish Malik, Senior Lecturer, **Loughborough University**

6.50am

11:50am

Phage Display – Powerful techniques in immunotherapy

- Understand the global economics of bacteriophage application
- Define protocols for isolation and selection of bacteriophages that are virulent against Vibrio cholerae to develop phage cocktail to control outbreaks
- Expanding on the current phage bank frameworks to ensure global distribution and access

Tobi Nagel, Founder & President, **Phages for Global Health**

7:10am

12:10pm

From Discovery to Manufacturing – Fully Integrated Solutions for Phage Product Development

Jiayi Zhang, Founder & Chief Executive Officer, **Start Bioservices**

7:30am

12:30pm

Break

8:30am

1:30pm

Philanthropy, [hysicians, & phages... pick up the phone!

- Describes the barriers and opportunities to bringing Phage Therapy to Physician
- Sketch the philanthropy landscape for phage therapy
- Share how Canada is one positive example of Physician and Philanthropic engagement

Greg German, Co-Founder, **Phage Canada**

PLAN YOUR DAY

8:50am 1:50pm **Globally effective, off-the-shelf phage products for agriculture application – results from the trials across the world.**

- The successful application of bacteriophages in poultry production, specifically in the prevention of Salmonella and E. coli infections
- Insights into Proteon studies and commercial application results from farms across the world, showcasing efficacy of products against diverse global strains
- Understanding the exceptional stability and off-the-shelf readiness of phage solutions

Justyna Kowalski, Head of Product Management, **Proteon Pharmaceuticals**

9:10am 2:10pm **Phase 2 study ("Tailwind") of inhaled AP-PA02 in patients with noncystic fibrosis bronchiectasis (NCFB) and chronic Pseudomonas aeruginosa respiratory infection**

Mina Pastagia, Chief Medical Officer, **Armata Pharmaceuticals**

9:30am 2:30 am **Results from phase 1a/2a randomized, double-blind, placebocontrolled study.**

Iddo Weiner, Vice President of Research, **BiomX**

9:50am 2:50pm **Break**

10:30am 3:30pm **The beast within: prophage challenges in manufacturing host selection**

- The removal of prophages in hosts for use in phage manufacturing

Robert McKee, Principal Scientist, **Locus Biosciences**

10:50am 3:50pm **Efficacy study of bacteriophage COP-80B for treatment of S. epidermidis prosthetic joint infection in mouse**

- In vitro and in silico bacteriophage COP-80B characterization
- Development of mice model (implant optimization, surgery protocol, etc)
- Pharmacokinetics and pharmacodynamic of COP-80B in mice model
- Efficacy of COP-80B for treatment of prosthetic joint infection in mice model and comparison with antibiotic treatment (preliminary)

Matjaz Peterka, Chief Executive Officer, **COBIK**

11:10am 4:10pm **Break**

PLAN YOUR DAY

- 12:00pm 5:00pm **Panel Discussion: Regulatory considerations for bacteriophage therapy**
- Navigate the current regulatory status of phage for commercial and therapeutic use
 - Differences in regulation between human and animal applications
 - Identify common regulatory hurdles related to GMP phage production and manufacturing

- 12:20pm 5:20pm **Funding – How to build a good business model and attract investment**
- How to build an innovative phage pipeline that will draw investment
 - Explore how to build a good business model and interact successfully with investors
 - Know how investors direct their funding and resources in the phage industry

Joseph Campbell, Research Resources Project Officer, **NIH**

- 12:40pm 5:40pm **Salt in My Soul: An unfinished life**
- Mallory Smith passed away from a superbug at the age of 25, two months after she received a double lung transplant. As she was dying, her father moved mountains to get an experimental treatment called phage therapy for her; a treatment that had been used 100 years ago before penicillin was discovered. Once it was, penicillin's patent protection and financial incentives rendered work on phage therapy obsolete. The United States Navy responded to Mallory's story and provided the phage therapy cocktail that Mallory received. Tragically, it didn't arrive in time to save her, but the autopsy revealed that it had started to work – and would have saved her life if she had gotten it earlier. Diane Shader Smith shares this riveting story about mobilizing the medical community and the power each of us has to make a difference.

Diane Shader Smith, Author and Cystic Fibrosis Advocate

**PATIENT
STORY**

“Phage Futures is my favourite conference of the year! The who's who of fundamental phage biology, phage therapy, and regulatory show up in force, and I always learn new things every year!”

LOCUS BIOSCIENCES

PARTNERSHIP OPPORTUNITIES

Be the answer to the industry's questions by showcasing your company in a new light. Raise your profile and form new partnerships with more opportunities for meaningful interactions.

Why Partner with us?

- ✓ Be recognised as an industry leader
- ✓ Get the eyes of hundreds of decision-makers on your brand
- ✓ Create space for the most important conversations, and the ones you never knew were out there
- ✓ Fuel your pipeline for 2024 and beyond
- ✓ Network with the industry elite
- ✓ Amplify your biggest announcements, research, and expertise

GET IN TOUCH

Want to know more? We're here to help you find out all about our sponsorship options including:

THOUGHT LEADERSHIP

Presentations, Panel Discussions and Workshops

NETWORKING

1-1 Meetings, Digital Boardrooms, Online Networking Platform

BRAND AWARENESS

Marketing Campaigns, Advertising, Presentations, Content and Resources

CONTACT
US TODAY



Simon Pickles
Commercial Partnerships Director
Simon.pickles@kisacoresearch.com

READY TO REGISTER?

BOOK YOUR FREE TICKET TODAY

In 2023 we are thrilled to be reuniting the Phage Futures community, providing a space where phage researchers, from across the globe, can connect. We are committed to making Phage Futures as accessible as possible.

For this reason, the summit will be run digitally, free to attend, and open to all. If you'd like to support the summit, contribute to the program, and engage with our community, please email **partner@kisacoresearch.com** for more information on our sponsorship opportunities.

To secure your place at the summit and to access the digital platform, register for your free pass today!

REGISTER NOW

This is a really superb meeting. It's so well run, and the lineup is always very exciting! It's a huge pleasure and very beneficial in all sorts of ways. Highly recommended!

Cellexus

"Phage Futures was great for learning about novel phage research and networking with big players in the phage world."

Yale University

"Phage Futures connects both industry and academia such that research can be scaled to greater heights for better accessible patient care. Networking with so many industry experts was a huge benefit for me and I would highly recommend attending Phage Futures in the future"

University of Warwick

"Phage Futures endeavours every year to put together an extraordinary program encompassing the most recent advances in the clinical application of bacteriophages and commercially viable non-traditional therapeutics."

PhageLux